BRAF mutant colorectal cancer: Prognosis, treatment, and new perspectives

Annals of Oncology

Volumn 28, Issue 11, 2017, Pages 2648-2657

  Sanz Garcia, E ^a,b   Argiles, G ^a,b   Elez, E ^a,b   Tabernero, J ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Anti EGFR; BRAF; Clinical trials; Colorectal cancer; Targeted therapy

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; ALANINE AMINOTRANSFERASE; ALPELISIB; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; BINIMETINIB; BUPARLISIB; CETUXIMAB; DABRAFENIB; DACTOLISIB; ENCORAFENIB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLX 3603; RIBOCICLIB; RO 5212054; TRAMETINIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VEMURAFENIB; WNT 974; BRAF PROTEIN, HUMAN;

ABDOMINAL PAIN; ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAF GENE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER THERAPY; CHILL; COLORECTAL CANCER; DECREASED APPETITE; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE EXPRESSION; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKERATOSIS; HYPONATREMIA; HYPOPHOSPHATEMIA; INSOMNIA; LEUKOPENIA; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NEXT GENERATION SEQUENCING; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RASH; RECURRENCE FREE SURVIVAL; REVIEW; RNA TRANSLATION; SIDE EFFECT; SKIN CARCINOMA; THERAPY RESISTANCE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; COLORECTAL TUMOR; GENETICS; MUTATION; PROGNOSIS;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 85034063044     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx401     Document Type: Review

References (81)

1. Ascierto PA, Kirkwood JM, Grob JJ et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012; 10: 85
2. Lea IA, Jackson MA, Li X et al. Genetic pathways and mutation profiles of human cancers: site-and exposure-specific patterns. Carcinogenesis 2007; 28: 1851-1858
3. Cox AD, Fesik SW, Kimmelman AC et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014; 13: 828-851
4. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10: 385-394
5. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114
6. Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101: 465-472
7. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937
8. Tran B, Kopetz S, Tie J et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-4632
9. Yokota T, Ura T, Shibata N et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-862
10. Tie J, Gibbs P, Lipton L et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128: 2075-2084
11. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867
12. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
13. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
14. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634
15. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507
16. Rad R, Cadinanos J, Rad L et al. A genetic progression model of BrafV600E-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013; 24: 15-29
17. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793
18. Deng G, Bell I, Crawley S et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191-195
19. Gonsalves WI, Mahoney MR, Sargent DJ et al. Patient tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 2014; 106: 8
20. Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 2013; 15: e711-e718
21. Ogino S, Brahmandam M, Cantor M et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006; 19: 59-68
22. Naguib A, Mitrou PN, Gay LJ et al. Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer 2010; 10: 99
23. Yaeger R, Cercek A, Chou JF et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120: 2316-2324
24. Farina-Sarasqueta A, van Lijnschoten G, Moerland E et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402
25. Roth AD, Tejpar S, DelorenziMet al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474
26. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-6069
27. Lochhead P, Kuchiba A, Imamura Y et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105: 1151-1156
28. Sinicrope FA, Mahoney MR, Smyrk TC et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013; 31: 3664-3672
29. Venderbosch S, Nagtegaal ID, Maughan TS et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20: 5322-5330
30. Seligmann JF, Fisher D, Smith CG et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol 2017; 28: 562-568
31. Renaud S, Romain B, Falcoz PE et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer 2015; 112: 720-728
32. Schirripa M, Bergamo F, Cremolini C et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112: 1921-1928
33. Cremolini C, Di Bartolomeo M, Amatu A et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol 2015; 26: 2092-2097
34. Morris V, Overman MJ, Jiang ZQ et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAFmutated colorectal cancer. Clin Colorectal Cancer 2014; 13: 164-171
35. Loupakis F, Cremolini C, Salvatore L et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63
36. Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315
37. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721
38. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712
39. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762
40. Bokemeyer C, Van Cutsem E, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475
41. Smith CG, Fisher D, Claes B et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/-cetuximab. Clin Cancer Res 2013; 19: 4104-4113
42. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
43. Stintzing S, Jung A, Rossius L et al. Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014; 32: 445
44. Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 14: 749-759
45. Karapetis CS, Jonker D, Daneshmand Met al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014; 20: 744-753
46. Peeters M, Oliner KS, Parker A et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013; 19: 1902-1912
47. Peeters M, Oliner KS, Price TJ et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014; 32: 3568-3568
48. Pietrantonio F, Petrelli F, Coinu A et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-594
49. Rowland A, Dias MM, Wiese MD et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-1894
50. Kopetz S, Desai J, Chan E et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015; 33: 4032-4038
51. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819
52. Hyman DM, Puzanov I, Subbiah V et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373: 726-736
53. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103
54. Corcoran RB, Ebi H, Turke AB et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer. Discov 2012; 2: 227-235
55. Mao M, Tian F, Mariadason JM et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-667
56. Krejci P, Aklian A, Kaucka M et al. Receptor tyrosine kinases activate canonical WNT/beta-catenin signaling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation. PLoS One 2012; 7: e35826
57. Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv Cancer Res 2008; 99: 113-333
58. Rad R, Cadinanos J, Rad L et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013; 24: 15-29
59. Cancer GAN. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337
60. Yaeger R, Cercek A, O'Reilly EM et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21: 1313-1320
61. Van Cutsem E, Atreya C, André T et al. LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Oncol 2015; 26: iv119
62. Atreya CE, Van Cutsem E, Bendell JC et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33: 103
63. Corcoran RB, André T, Yoshino T et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Oncol 2016; 27: 455O-455O
64. Gomez-Roca CA, Delord J, Robert C et al. 535P Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion in an open-label, phase 1 study. Ann Oncol 2014; 25: iv182-iv183
65. Tabernero et al. Drug combo beneficial in colorectal cancer. Cancer Discov 2015; 5: 102
66. Elez E, Schellens J, van Geel R et al. LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer. Ann Oncol 2015; 26: iv120
67. van Geel R, Tabernero J, Elez E et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAFmutant colorectal cancer. Cancer Discov 2017; 7: 610-619
68. Tabernero J, Geel RV, Guren TK et al. Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). J Clin Oncol 2016; 34: 3544
69. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 2012; 367: 1694-1703
70. Corcoran RB, Atreya CE, Falchook GS et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015; 33: 4023-4031
71. Juric D, Castel P, Griffith M et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor. Nature 2015; 518: 240-244
72. Yang H, Higgins B, Kolinsky K et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72: 779-789
73. Hong DS, Morris VK, El Osta B et al. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 2016; 6: 1352-1365
74. Kopetz SMS, Morris VK, Lenz H. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017; 35: Abstract 520
75. Oddo D, Sennott EM, Barault L et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res 2016; 76: 4504-4515
76. Ahronian LG, Sennott EM, Van Allen EM et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015; 5: 358-367
77. Pietrantonio F, Oddo D, Gloghini A et al. MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer. Cancer Discov 2016; 6: 963-971
78. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356
79. Popovici V, Budinska E, Tejpar S et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2012; 30: 1288-1295
80. Vecchione L, Gambino V, Raaijmakers J et al. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell 2016; 165: 317-30
81. Barras D, Missiaglia E, Wirapati P et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 2017; 23: 104-115